Shinpoong Pharmaceutical Co (XKRX:019170) Notes Receivable: ₩0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKRX:019170 Shinpoong Pharmaceutical Co Ltd XKRX:019170
65 GF Score
Price ₩10,070.00
GF Value ₩11,211.69
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Shinpoong Pharmaceutical Co Notes Receivable?

Shinpoong Pharmaceutical Co XKRX:019170 +0.50% 65 Notes Receivable is ₩0 Mil as of Jun. 2026. GuruFocus rates XKRX:019170 with a GF Score™ of 65/100 and a GF Value™ of ₩11,211.69 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Shinpoong Pharmaceutical Co's Notes Receivable for the quarter that ended in Jun. 2026 was ₩0 Mil.

Shinpoong Pharmaceutical Co Notes Receivable Related Terms

Shinpoong Pharmaceutical Co Notes Receivable Historical Data

* Premium members only.

The historical data trend for Shinpoong Pharmaceutical Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shinpoong Pharmaceutical Co Notes Receivable Chart

Shinpoong Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Shinpoong Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XKRX:019170
65GF Score
Shinpoong Pharmaceutical Co Ltd XKRX:019170
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shinpoong Pharmaceutical Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₩0 Mil mean?
Shinpoong Pharmaceutical Co (XKRX:019170) has a Notes Receivable of ₩0 Mil as of Jun. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Shinpoong Pharmaceutical Co and its competitors.
Is Shinpoong Pharmaceutical Co's Notes Receivable too high?
Shinpoong Pharmaceutical Co's current Notes Receivable is ₩0 Mil. Overall, Shinpoong Pharmaceutical Co has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shinpoong Pharmaceutical Co's Notes Receivable compare to ZTS?
Shinpoong Pharmaceutical Co's Notes Receivable of ₩0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Shinpoong Pharmaceutical Co and its competitors. Shinpoong Pharmaceutical Co's current Notes Receivable is ₩0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shinpoong Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shinpoong Pharmaceutical Co (XKRX:019170) is currently considered Modestly Undervalued. The stock's GF Value™ is ₩11,211.69, compared to a current price of ₩10,070.00 — trading 10.2% below its estimated fair value. The current Notes Receivable is ₩0 Mil. Shinpoong Pharmaceutical Co's overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Shinpoong Pharmaceutical Co (XKRX:019170), the current Notes Receivable is ₩0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shinpoong Pharmaceutical Co (XKRX:019170) Overvalued in 2026?

Based on GuruFocus' analysis, Shinpoong Pharmaceutical Co stock appears to be undervalued. The current stock price of ₩10,070.00 is trading 10.2% below its estimated GF Value™ of ₩11,211.69. GuruFocus considers Shinpoong Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for XKRX:019170:

  • Notes Receivable: ₩0 Mil
  • GF Value™: ₩11,211.69 vs. price of ₩10,070.00 (10.2% below fair value)
  • GF Score™: 65/100 with 1 warning sign

No single metric tells the full story. See the XKRX:019170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shinpoong Pharmaceutical Co Business Description

Other Exchanges 019175:Korea
Address 161, Yeoksam-ro, Gangnam-gu, Seoul, KOR, 06246
Shinpoong Pharmaceutical Co Ltd specializes in manufacturing remedy drugs and also active pharmaceutical ingredients and finished products. Its products include Newsicam, Caravenal, Roxagen, Clamoxin duo, Ceroxim, and Clocin. The firm's production facilities are located at Gyeonggi-do and Cheongwon-gun.
65GF Score

Get the complete analysis for XKRX:019170

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₩10,070.00
Price
₩11,211.69
GF Value